RG-7410

RG-7410
Clinical data
Other namesRG7410
Routes of
administration		Unspecified[1]
Drug classTrace amine-associated receptor 1 (TAAR1) agonist[1]

RG-7410 is a trace amine-associated receptor 1 (TAAR1) agonist which was under development for the treatment of schizophrenia but was never marketed.[1][2] Its route of administration was unspecified.[1]

The drug reached phase 1 clinical trials prior to the discontinuation of its development.[1][2] It was under development by Hoffmann-La Roche.[1][2] RG-7410 was first disclosed by January 2014[3] and a phase 1 trial was reported to have been completed by October 2014.[4]

  1. ^ a b c d e f "RG 7410". AdisInsight. 13 October 2015. Retrieved 23 October 2024.
  2. ^ a b c "Delving into the Latest Updates on RG-7410 with Synapse". Synapse. 19 September 2024. Retrieved 23 October 2024.
  3. ^ https://assets.roche.com/f/176343/b9882c9bf5/irp140130.pdf
  4. ^ https://jamesjungkuelee.wordpress.com/wp-content/uploads/2015/01/jpm-2015-roche.pdf